The Federal Trade Commission’s biggest settlement to date—$1.2 billion in a pay-for-delay case—came out of federal court in Philadelphia on Thursday.
Cephalon, now owned by Teva Pharmaceutical Industries, agreed to settle a suit filed by the FTC in 2008 over the company’s reverse-payment arrangements with generic drugmakers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]